Pivot Pharma Licenses Thrudermic Transdermal Nanotechnology and Expands Scientific Advisory Board

VANCOUVER, BC--(Marketwired - Nov 9, 2017) - Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) ("Pivot" or the "Company") is pleased to announce the signing of a Binding Letter of Intent with Thrudermic, LLC, a privately held North Carolina company, to acquire worldwide rights to Thrudermic's Transdermal Nanotechnology for the development and commercialization of topical cannabinoids. In addition, Dr. Joseph Borovsky and Dr. Leonid Lurya, Thrudermic's Chief Executive Officer and Chief Technology Officer, respectively, have been appointed to Pivot's Scientific Advisory Board.

Thrudermic drug delivery technology was developed and tested in collaboration with a multi-national pharmaceutical company. The technology is suitable for human delivery and provides the ability to specifically formulate individual drugs to control and prolong drug release while maintaining steady therapeutic concentrations. The use of lipid-based nano dispersion with topical cannabinoids allows for considerably higher concentrations of a drug in Pivot's planned formulations compared to other available technologies. Notably, Thrudermic can handle water soluble and water insoluble drugs, while causing no change to the skin morphology or sensitivity to the digestive system.

"Thrudermic is very excited to collaborate with Pivot to develop transdermal products containing cannabinoid extracts by using our lipid-based nano dispersion technology. By increasing bioavailability, drug release rates and stability, patients should be able to confidently take correct and accurate doses to help with their therapeutic needs," states Thrudermic CEO Dr. Joseph Borovsky.

Dr. Borovsky, formerly the director of R&D for Mead Corporation, received his Bachelor of Science degree in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry at Washington State University College of Pharmacy and was a Research Fellow in Synthetic Organic Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of Science, Israel.